Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Manitoba

$17,500.00

Canada Graduate Scholarships Masters CIHR

FY 2022-23

Summary
Brain disorders cause significant patient suffering and place further stress on our healthcare systems. Rett syndrome (RTT) is a severe developmental brain disorder that affects females, causing language and motor problems at a young age. Improving the quality of life of children living with RTT remains an unmet global priority, with few effective treatments available. To develop next-generation RTT therapeutics, we must advance our understanding of the events occurring during brain development. The underlying disease may be due to an initial malfunction of just a few cells. Therefore to understand the origins of RTT at the whole brain level, it is essential to measure the health of individual cells. Recent studies have shown that mutations in the DNA repair gene Fan1 improved the health and life span of mice with RTT Mecp2 null mutations, indicating it could attenuate the severity of neurological disorders. To test if Fan1 has unique cell-type-specific functions in a mouse model of RTT, we will generate novel genetic Mosaic Analysis with Double Markers (MADM) mouse models. MADM is a system that allows cells with two different genotypes to be generated within the same tissue and for cells of each genotype to be identified with a different fluorescent marker. An increased understanding of the neurobiology of RTT may ultimately lead to the development of individually targeted treatment programs. Of direct relevance to child health in Canada, MADM technology will allow us to identify key molecular changes occurring in each cell type in the brain as RTT develops and how Fan1 might help prevent severe disease from forming. This information may eventually be used to verify the effectiveness of future therapeutic approaches before their translation to human trials.
Program
Master's Award: Canada Graduate Scholarships
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486109
Name
Quinlan Kaitlyn
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Canada Graduate Scholarships Masters CIHR
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Fan1; Genetic Disorders; Madm; Mecp2; Neural Stem Cells; Neurodevelopment; Neurodevelopmental Disorders; Neurological Disorders; Neuroscience; Rett Syndrome
Abstract
Brain disorders cause significant patient suffering and place further stress on our healthcare systems. Rett syndrome (RTT) is a severe developmental brain disorder that affects females, causing language and motor problems at a young age. Improving the quality of life of children living with RTT remains an unmet global priority, with few effective treatments available. To develop next-generation RTT therapeutics, we must advance our understanding of the events occurring during brain development. The underlying disease may be due to an initial malfunction of just a few cells. Therefore to understand the origins of RTT at the whole brain level, it is essential to measure the health of individual cells. Recent studies have shown that mutations in the DNA repair gene Fan1 improved the health and life span of mice with RTT Mecp2 null mutations, indicating it could attenuate the severity of neurological disorders. To test if Fan1 has unique cell-type-specific functions in a mouse model of RTT, we will generate novel genetic Mosaic Analysis with Double Markers (MADM) mouse models. MADM is a system that allows cells with two different genotypes to be generated within the same tissue and for cells of each genotype to be identified with a different fluorescent marker. An increased understanding of the neurobiology of RTT may ultimately lead to the development of individually targeted treatment programs. Of direct relevance to child health in Canada, MADM technology will allow us to identify key molecular changes occurring in each cell type in the brain as RTT develops and how Fan1 might help prevent severe disease from forming. This information may eventually be used to verify the effectiveness of future therapeutic approaches before their translation to human trials.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Quinlan, Kaitlyn
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~
University of Manitoba - $17,500 Grant (2022-23) | Canada Spends